European partnerships invest £27.4m to accelerate cancer research

Cancer Research UK Accelerator Awards programme provides 5 years of funding for international projects

Cancer Research UK and its European partners, Fondazione AIRC and Asociación Española Contra el Cáncer (AECC), are to invest £27.4 million into seven new international projects to accelerate lifesaving cancer research. 

The Cancer Research UK Accelerator Awards programme, which provides five years of funding for international projects, reflects a longstanding link between the UK and Europe, working together to drive progress for people affected by cancer.

The successful teams will develop new research tools, resources and infrastructure to improve scientists’ understanding of cancer, including rare and hard-to-treat cancers, helping to find better ways to treat them. Projects include investigating how to best combine radiotherapy with the latest immunotherapies, and refocussing research efforts on mesothelioma, an asbestos-related cancer, cases of which continue to rise globally.

The Accelerator Awards bring together world-class researchers who would not previously have been able to work together, without the unique structure of this grant scheme. Each collaboration aims to deepen the research community’s understanding of cancer and bring people with cancer closer to new treatments, making use of the expertise and diverse technologies of different partner organisations.

Professor Paul French, a physicist based at Imperial College London, will lead one of the projects to improve the way we develop and test anti-cancer drugs in the lab.
Traditionally, drug discovery research has used thin ‘2D’ layers of cells that can be easily controlled and imaged on conventional microscopes. However, such simplified disease models don’t adequately represent the complex 3D cancer environment within the body.

Professor Kevin Blyth, a clinician scientist based at the University of Glasgow, will lead another of the projects, focussed on finding better treatments for mesothelioma, a hard-to-treat asbestos-related cancer that most commonly starts in the layers of tissue that cover each lung.

Dr Iain Foulkes, executive director of research and innovation at Cancer Research UK, said: “If current trends continue, the world will see a 60% increase in cancer cases over the next two decades. Cancer is a global problem and no one country can tackle it alone.

“Now the UK has left the European Union, the need to retain collaborative cancer research between the EU and the UK has never been greater. This partnership will also strengthen UK cancer research by the sharing of expertise, new technologies and research talent.”

Professor French said: “The complexity of cancer is beyond our current understanding and existing therapies. By developing technology to investigate more sophisticated 3D cancer models, which allow us to explore how drugs work on tumour cells interacting with their local environment, we could find new ways to overcome challenges like drug resistance.”

Professor Blyth commented: “In the future it’s likely that the global incidence of mesothelioma will continue to increase, as there are many countries that still don’t regulate the use of asbestos. So, it’s important to build a research community now and improve our understanding to help those affected by this cancer.”

The next round of the Accelerator Awards will open on 2 March for international research groups. For more information, visit: www.cancerresearchuk.org.